Clinical Trial Update: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study of GSK2816126 in relapsed/refractory B-cell and solid tumor malignancies terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphomas
• Solid Tumors
• Transformed Follicular Lymphoma

Drugs mentioned

• GSK2816126

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer, Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2019-06-28